One Year After Finisar Acquisition, II-VI Eyes Power Market Growth - IDEX Health & ScienceIDEX Health & Science

    Disclaimer:

    The views, information, or opinions expressed in the Industry News RSS feed belong solely to the author and do not necessarily represent those of IDEX Health & Science and its employees.

    One Year After Finisar Acquisition, II-VI Eyes Power Market Growth

    Article obtained from Photonics RSS Feed.

    II-VI reported $728.1 million in revenue and earnings per share (EPS) of 84 cents (GAAP EPS of 38 cents) for its first quarter, ending Sept. 30. Operating income for the quarter exceeded $138 million and $100 million (GAAP).

    EPS surpassed the Zacks consensus estimate by nearly 30 cents. The company narrowly fell short of Zacks’ projected revenue total, by less than $1 million.

    The quarterly revenue total more than doubles that which the company achieved in the three-month period ending Sept. 30 in 2019, in which II-VI reported quarterly revenue of $340.4 million. The total is down from the $746.2 revenue total that concluded the company’s previous (fourth) quarter. EPS dropped for the quarter by 34 cents. II-VI…

    READ MORE
    Nov, 05 2020 |

    IDEX Health & Science is the global authority in fluidics and optics, bringing to life advanced optofluidic technologies with our products, people, and engineering expertise. Intelligent solutions for life.